Published in Drug Week, September 2nd, 2005
Thiovir also exhibited a slightly higher level of antiviral activity against HIV-1 than foscarnet, a currently marketed, broad spectrum antiviral indicated for treatment of opportunistic infections in HIV patients. A poster of the study data was presented at the 3rd International AIDS Society Conference (IAS 2005) on HIV Pathogenesis...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.